High plasma d-dimer level is associated with decreased survival in patients with lung cancer

Basit Öğe Kaydı
dc.authorwosid, Osman/AGR-7980-2022
dc.authorwosid, osman/HRD-6024-2023
dc.contributor.authorAltiay, G.
dc.contributor.authorCiftci, A.
dc.contributor.authorDemir, M.
dc.contributor.authorKocak, Z.
dc.contributor.authorSut, N.
dc.contributor.authorTabakoglu, E.
dc.contributor.authorHatipoglu, O. N.
dc.date.accessioned2024-06-12T10:59:10Z
dc.date.available2024-06-12T10:59:10Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAims: An elevated plasma D-dimer level indicates the activation of coagulation and fibrinolysis. In the present study, we investigated the association of pre-treatment haemostatic parameters (D-dimer, fibrinogen and prothrombin fragment 1 + 2) with clinicopathological parameters and outcome in patients with lung cancer. Materials and methods: Plasma levels Of D-dimer and other parameters were measured in 78 evaluable patients with lung cancer (60 non-small cell lung cancers, 18 small cell lung cancers). At diagnosis, 35 patients (44.9%) were locally advanced stage (IIIA/B) and 43 patients (55.1%) had metastatic disease (IV). Multivariate statistical analysis was carried out using Cox's proportional hazards model. The receiver operating characteristic curve was used to determine the cutoff values for D-dimer, fibrinogen and prothrombin fragment 1 + 2. Results: The median survival for all patients was 264 days (95% confidence interval 200-328 days). A significant association between the plasma levels Of D-dimer and the response to chemotherapy was observed (P = 0.03). With the univariate analysis, tumour stage, pre-treatment plasma levels Of D-dimer, fibrinogen, platelet count, lactate dehydrogenase concentration and Karnofsky performance status were predictive for survival. With the multivariate analysis (P <= 0.11), the plasma level Of D-dimer (P < 0.001), tumour stage (P = 0.01) and Karnofsky performance status (P = 0.02) were identified as independent predictive factors. The median survival times were 405 days (95% confidence interval 165-644 days) and 207 days (95% confidence interval 146-267 days, P < 0.001), respectively, for patients with a low D-dimer level (<= 0.65 mu g/ml) and a high D-dimer level (> 0.65 mu g/ml). Conclusions: Elevated plasma levels Of D-dimer in patients with lung cancer are associated with decreased survival and a poor response to treatment. Pre-treatment for the D-dimer level may be useful in the prediction of survival and the response to treatment.en_US
dc.identifier.doi10.1016/j.clon.2007.04.002
dc.identifier.endpage498en_US
dc.identifier.issn0936-6555
dc.identifier.issn1433-2981
dc.identifier.issue7en_US
dc.identifier.pmid17513096en_US
dc.identifier.scopus2-s2.0-34547540188en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage494en_US
dc.identifier.urihttps://doi.org/10.1016/j.clon.2007.04.002
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20345
dc.identifier.volume19en_US
dc.identifier.wosWOS:000249231500003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Londonen_US
dc.relation.ispartofClinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectD-Dimeren_US
dc.subjectLung Canceren_US
dc.subjectPrognosisen_US
dc.subjectMolecular-Weight Heparinen_US
dc.subjectPrognostic-Significanceen_US
dc.subjectTumor Stageen_US
dc.subjectCoagulationen_US
dc.subjectAnticoagulationen_US
dc.subjectAbnormalitiesen_US
dc.subjectCarcinomaen_US
dc.subjectSystemen_US
dc.titleHigh plasma d-dimer level is associated with decreased survival in patients with lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu